Elicio Therapeutics, Inc. (ELTX) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
The consensus price target is $17.00, representing an upside of 44.3% from the current price $11.78.
Analysts estimate Earnings Per Share (EPS) of $-4.07 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.25 vs est $-4.07 (missed -4.6%). 2025: actual $-2.58 vs est $-2.51 (missed -3%). Analyst accuracy: 96%.
ELTX Stock — 12-Month Price Forecast
$17.00
▲ +44.31% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for Elicio Therapeutics, Inc., the price target is $17.00.
The average price target represents a +44.31% change from the last price of $11.78.
ELTX Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Elicio Therapeutics, Inc. in the past 3 months
EPS Estimates — ELTX
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.25
vs Est –$4.07
▼ 4.4% off
2025
Actual –$2.58
vs Est –$2.51
▼ 2.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ELTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
